More from the Author

• Supplement | HBS Case Collection | February 2016 (Revised March 2020)

  Oberoi Hotels: Train Whistle in the Tiger Reserve

  Ananth Raman and Ryan W. Buell

  Citation:

  Raman, Ananth, and Ryan W. Buell. "Oberoi Hotels: Train Whistle in the Tiger Reserve." Harvard Business School Multimedia/Video Supplement 616-704, February 2016. (Revised March 2020.)  View Details

  CiteView DetailsPurchase

  Related

• Teaching Note | HBS Case Collection | February 2016 (Revised February 2020)

  Oberoi Hotels: Train Whistle in the Tiger Reserve

  Ryan W. Buell and Ananth Raman

  Celebrated as one of the world's premiere luxury hotel brands, Oberoi Hotels attracts and serves some of the most quality sensitive guests in the world. The case considers the challenge of how an organization with a standardized service model can repeatedly delight customers whose expectations grow with every interaction. To explore this question, the case details the design elements of Oberoi's complex service operation, including its approaches to employee management and continuous improvement, as well as the dynamics of service competition in a rapidly growing market.

  Keywords: service quality; service management; service quality competition; Customer Management; Customer Service Excellence; Employee empowerment; employee engagement; employee training; hospitality; hotel industry; Service Delivery; Service Operations; Customer Satisfaction; Employees; Training; Quality; Accommodations Industry; India;

  Citation:

  Buell, Ryan W., and Ananth Raman. "Oberoi Hotels: Train Whistle in the Tiger Reserve." Harvard Business School Teaching Note 616-044, February 2016. (Revised February 2020.)  View Details

  CiteView DetailsPurchase

  Related

• Case | HBS Case Collection | November 2018

  David Hysong and SHEPHERD Therapeutics

  Ananth Raman, John Masko and Aldo Sesia

  In 2016, David Hysong, at age 27, found out he had a rare, incurable cancer. Rather than wait around to die, Hysong, a recent graduate of Harvard Divinity School, decided to launch a biotechnology company called Shepherd Therapeutics to development treatments for his and other rare cancers. Two years later, the company had several drugs in promising stages of development but were at least 3 to 5 years away from commercialization, if they made it through clinical trials successfully. Only about 4% of drugs that enter clinical trials receive U.S. FDA approval. It is October 2018, and Shepherd is running out of money. Hysong needs to raise $5 million to fund operations for 2019 and at least $20 million for the following few years. But the company is too early to attract the type of venture capital he needs. Even if he got financing, Hysong worried that the company’s mission could be compromised by investors more interested in a return on their investment than saving lives, and he worried about the scaling challenges ahead.

  Keywords: cancer; therapeutics; drugs; Health Care and Treatment; Business Startups; Product Development; Financing and Loans; Growth and Development Strategy; Problems and Challenges;

  Citation:

  Raman, Ananth, John Masko, and Aldo Sesia. "David Hysong and SHEPHERD Therapeutics." Harvard Business School Case 619-012, November 2018.  View Details

  CiteView DetailsEducators

  Related